Monoclonal antibodies for migraine: an update by Castle, Daniel & Robertson, Neil P.
Vol.:(0123456789) 
Journal of Neurology 
https://doi.org/10.1007/s00415-018-8886-8
JOURNAL CLUB
Monoclonal antibodies for migraine: an update
Daniel Castle1 · Neil P. Robertson1
 
© The Author(s) 2018
Introduction
Migraine is an episodic neurological disorder resulting in 
attacks of headache associated with neurological symptoms. 
Whilst episodes of migraine are debilitating for the patient, 
they also result in a significant burden for society as a whole. 
The World Health Organisation now ranks migraine as the 
third most prevalent medical condition in the world, and the 
second most disabling neurological condition. The economic 
cost of migraine is also considerable and has an estimated 
worldwide annual cost of $20 billion, relating to healthcare, 
procedures and loss of productivity.
A number of therapeutic avenues have been explored to 
combat migraines over the decades, with perhaps the most 
significant milestone occurring in the 1990s with the intro-
duction of serotonin 5-HT1B/1D receptor agonists which 
led to improvement in the management of acute migraine, 
albeit with some continuing concerns regarding cardiovas-
cular side effects. However, despite the widespread use of 
these medications, only a third of patients have sustained 
freedom from pain.
The relevance of calcitonin gene-related peptides (CGRP) 
in the pathophysiology of migraine was first identified in 
1990 by Goadsby et al. who established that CGRP levels 
were increased in the cranial venous outflow during acute 
genuine migraine attacks. Further studies demonstrated that 
those treated successfully with triptans during a migraine 
attack had a drop in their level of CGRP. Furthermore, 
peripheral infusion of CGRP induced an attack in those 
known to suffer with migraine but appeared to have little 
effect on healthy volunteers. As a result, a range of monoclo-
nal antibodies have been produced which target the peptide 
itself or its corresponding receptor.
This month’s journal club will review clinical trial results 
for a series of novel monoclonal antibodies that target CGRP 
in patients with migraine. The first paper examines the use 
of erenumab in the STRIVE study for episodic migraine; the 
second paper updates our understanding of fremanezumab 
for chronic migraine and finally galcanezumab in episodic 
migraine.
A controlled trial of erenumab for episodic 
migraine
In this well publicised international multicentre, ran-
domised, double-blind, placebo-controlled, parallel-group 
phase three trial, Goadsby et al. investigated the efficacy of 
the drug erenumab in treating episodic migraine. Erenumab 
is a monoclonal antibody directed against the canonical 
CGRP receptor. In this study, 955 patients were randomly 
allocated to receive a subcutaneous injection of erenumab 
70 mg, erenumab 140 mg or placebo once a month for 6 
months. Participants were assessed over a 4-week period 
to ensure they met trial inclusion criteria as well as estab-
lishing a baseline data set. This included data on migraine 
frequency, medication use and functional impact of migraine 
as measured through a daily electronic diary of migraine and 
headache symptoms.
The study demonstrated a statistically significant fall in 
migraine days from baseline assessment, when adjusted 
for placebo, of 1.4 days in the 70 mg group and 1.9 in the 
140 mg group. There was also a 50% reduction in migraine 
days when adjusted for placebo seen in 23.4% of patients in 
the 140 mg cohort and 16.7% in the 70 mg. Secondary out-
comes included statistically significant reductions compared 
to placebo in use of acute migraine-specific medications and 
patient functional abilities as assessed with migraine physi-
cal function impact diary. Similar rates of adverse incidents 
were observed across all 3 cohorts with mild to moderate 
needle site injection reactions being most common. No car-
diac or liver abnormalities were observed but 35 out of 628 
post baseline antibody tests were positive to anti-erenumab 
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antibodies with one patient in the 70 mg group developing 
neutralising antibodies.
Comments: This well-powered and designed study has 
demonstrated the potential benefits of erenumab in episodic 
migraine management. However, as noted by the authors, a 
limitation of this study was the exclusion of patients who had 
had a lack of therapeutic response to more than two classes of 
migraine preventative drugs as well as women of childbear-
ing potential. Inclusion of these patient groups clearly offers 
challenges, but since refractory females of childbearing age 
may be a highly relevant target group for this drug, the addi-
tional complexities may have been worth it.
Goadsby et al. (2017) New England Journal of Medicine 
30;377(22):2123–2132
Fremanezumab for the preventive treatment 
of chronic migraine
This paper by Silberstein et  al. examines treatment of 
chronic migraine with fremanezumab, an antibody that binds 
to CGRP itself. This double-blind, randomised, placebo-
controlled phase 3 trial assessed 3148 participants over a 
4-week baseline period, recruiting 1130 eligible patients. 
Participants were divided into a placebo, monthly and quar-
terly group. Each group received a subcutaneous injection 
once a month, with the monthly group receiving freman-
ezumab every month and the quarterly group receiving 
fremanezumab on the first injection and placebo thereaf-
ter. Functional outcomes were assessed with an electronic 
diary and headache impact test questionnaire. The primary 
outcome was reduction of headache days compared with 
baseline. A headache day was defined as any day in which 
head pain lasted ≥ 4 consecutive hours with a peak severity 
of at least moderate, or the use of acute migraine medica-
tions. Secondary outcomes included drug safety profiling, 
reduction in migraine days and percentage reduction by 50%.
Fremanezumab demonstrated statistically significant 
improvement when adjusted for placebo and reduced head-
ache days by 1.8 days in the quarterly group and 2.1 days in 
the monthly group. Reduction in migraine days was also sig-
nificant, with 1.7 in the quarterly and 1.8 days reduction in 
the monthly group, when adjusted for placebo. Mild to mod-
erate needle site reactions were once again the most com-
mon adverse event. There was some evidence of transient 
liver function test derangement, but may have been related to 
concurrent medications. One participant on fremanezumab 
developed suicidal ideation leading to trial discontinuation.
Comments: The statistically significant treatment effect 
for headaches lasting over 4 h and to a lesser extent migraine 
is promising. However, the primary objective in this trial 
was reasonably vague and covered treatment of migraine 
and non-migrainous head pain, potentially complicating its 
indication. However, the study does suggest that freman-
ezumab is effective and also offers a unique and attractive 
treatment regimen of four times per year administration.
Silberstein et al (2017) New England Journal of Medicine 
30;377(22):2113–2122
Effect of different doses of galcanezumab 
vs placebo for episodic migraine prevention 
a randomised clinical trial
The final paper is a phase 2b placebo controlled, dose-
ranging study of galcanezumab (which selectively binds 
CRGP) in episodic migraine. 936 patients were reviewed 
over a screening and baseline period and 410 patients 
enrolled. Patients were randomised to monthly; placebo, 
5, 50, 120 and 300 mg intervention groups in a 2:1:1:1:1 
order, respectively. Patients received a subcutaneous injec-
tion once a month for 3 months with drug or placebo. Func-
tional outcomes were assessed by reporting to an automated 
phone line and completion of the headache impact test 
questionnaire.
The primary objective was to assess whether at least one 
dose of galcanezumab was superior to placebo in the preven-
tion of migraine, by reduction in migraine headache days 
(MHDs). MHD was defined as any calendar day in which a 
migraine headache lasted ≥ 30 min, the use of acute migraine 
treatment was not automatically counted as an MHD. After 
placebo adjustment, the 120 mg monthly cohort demonstrated 
the only statistically significant response, with a reduction in 
MHD of 1.1. Safety profiling demonstrated relatively good 
outcomes. Mild or moderate injection site reactions were com-
mon. One participant was diagnosed with Crohn’s disease, 
another treated for appendicitis and one developed suicidal ide-
ation, which the investigators felt were unrelated to the drug.
Comments: The level of MHD reduction observed, and 
proportion with 50% reduction of migraine days is compara-
ble if not inferior to some current therapies including topira-
mate, propranolol and acupuncture. As a result, an analysis 
of cost effectiveness is likely to be relevant and trials which 
consider these drugs against an active comparator would be 
enlightening. Although the safety profile was generally good, 
the participants in this and the previous study who developed 
suicidal ideation may be a feature to monitor going forward.
Skljaarevski et al (2018) JAMA Neurology 75(2):187–193
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